Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Late Polyclonal P-BCMA-101 CAR-T Cell Re-Expansion and Rapid Complete Response in a Patient with Relapsed Multiple Myeloma Treated with One Cycle of Talquetamab, More Than 3 Years after CAR-T Infusion

Anupama Deepa Kumar, Ajai Chari, Srishti Gupta, Joseph Rohr, Rajesh Belani, Blair Madison, Zhibo Ma, Chris E Martin, Katherine McArthur, Hilary Ostwald, Syed Rizvi, Thomas G Martin

Blood (2024) 144 (Supplement 1): 2083.

https://doi.org/10.1182/blood-2024-211578

Published: 2024

Journal Articles

A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort

Blood (2024) 144 (Supplement 1): 4828.

https://doi.org/10.1182/blood-2024-207459

Published: 2024

Journal Articles

A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

Susan O'Brien, Loretta J. Nastoupil, James Essell, Ly Dsouza, Doug Hart, Emiri Matsuda, Tarah Satterfield, Tonia Nesheiwat, Ashley Hammad, Franco Davi, Shally Chung, S. Asim Shamsi, Mara Bryan, Justin Skoble, Elizabeth Garner, Steven Kanner, Syed Rizvi, Houston Holmes

Blood (2022) 140 (Supplement 1): 9457–9458.

https://doi.org/10.1182/blood-2022-168128

Published: 2022

Journal Articles

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 22–25.

https://doi.org/10.1182/blood-2020-136307

Published: 2020

Journal Articles

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Deepu Madduri, MD, Saad Z. Usmani, MD, Sundar Jagannath, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M Schecter, MD, Sen Zhuang, Jeffrey R. Infante, MD, Syed Rizvi, Xiaohu (Frank) Fan, MD PhD, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD

Blood (2019) 134 (Supplement_1): 577.

https://doi.org/10.1182/blood-2019-121731

Published: 2019

Journal Articles

The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression

Blood (2019) 134 (Supplement_1): 5549.

https://doi.org/10.1182/blood-2019-122939

Published: 2019

Journal Articles

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Samantha Brocklehurst, Neil Desai, MD MHS, Jennifer L Shah, MD, Syed Rizvi, MD, Praveen Ramakrishnan Geethakumari, MD, Kiran A Kumar, MD MBA

Blood (2019) 134 (Supplement_1): 5262.

https://doi.org/10.1182/blood-2019-131246

Published: 2019

Journal Articles

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

Enrique Zudaire, PhD, Deepu Madduri, MD, Saad Z. Usmani, MD FACP, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD, Dong Geng, Syed Rizvi, MD, Tonia Nesheiwat, Jordan M Schecter, MD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Alicia J. Allred, PhD, Indrajeet Singh, PhD, Raluca Verona, PhD, Ian McCaffery, PhD, Sundar Jagannath

Blood (2019) 134 (Supplement_1): 928.

https://doi.org/10.1182/blood-2019-127309

Published: 2019

Journal Articles

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

David J. Andorsky, MD, Abdulraheem Yacoub, MD, Jacob D. Bitran, MD, Jason Melear, MD, Heather D. Brooks, MD BS, BA, Kenneth A. Foon, MD, Syed Rizvi, MD, Mary Llorente, Jiahui Li, PhD, Jeff P. Sharman, MD

Blood (2016) 128 (22): 1798.

https://doi.org/10.1182/blood.V128.22.1798.1798

Published: 2016

Journal Articles

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety

David S. Siegel, MD PhD, Gary J. Schiller, MD, Kevin W. Song, MD, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Fred J. Reu, Ehsan Malek, MD, Jorge L Mouro, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Syed Rizvi, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 4497.

https://doi.org/10.1182/blood.V128.22.4497.4497

Published: 2016

Journal Articles

Relationship Between Lenalidomide Dose Modification and Outcomes in Patients with Myelodysplastic Syndromes

Amy E. DeZern, MD MHS, Gary Binder, Albert Fliss, PhD, X. Henry Hu, MD PhD, Syed Rizvi, MD, Frank A. Corvino, Steven R. Arikian, MD, Andy Surinach, Jianyi Lee, B. Douglas Smith, MD

Blood (2015) 126 (23): 3286.

https://doi.org/10.1182/blood.V126.23.3286.3286

Published: 2015

Journal Articles

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

Mark Kirschbaum, MD, Ivana Gojo, MD, Stuart L. Goldberg, MD, Lisa Kujawski, Ehab Atallah, Peter Marks, MD, PhD, Donna Di Gravio, Lisa Pyle, Syed Rizvi, Jean-Pierre J Issa, MD

Blood (2009) 114 (22): 2089.

https://doi.org/10.1182/blood.V114.22.2089.2089

Published: 2009

Journal Articles

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Madeleine Duvic, MD, Youn H Kim, MD, Timothy M Kuzel, MD, Theresa R Pacheco, MD, Francine M Foss, Sareeta Parker, Syed Rizvi, Cong Chen, Jean Marie Arduino, ScD, Elise A. Olsen, MD

Blood (2009) 114 (22): 1709.

https://doi.org/10.1182/blood.V114.22.1709.1709

Published: 2009

Journal Articles

The Combined Safety and Tolerability Profile of Vorinostat-Based Therapy for Solid or Hematologic Malignancies.

David Siegel, Pamela N Munster, Eric Rubin, Marian Iwamoto, Simon van Belle, Mohamad Hussein, MD, Chandra P Belani, Francisco Robert, Evanthia Galanis, James Hardwick, Syed Rizvi

Blood (2009) 114 (22): 1710.

https://doi.org/10.1182/blood.V114.22.1710.1710

Published: 2009

Journal Articles

The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma.

Sundar Jagannath, MD, Donna Weber, MD, Ronald Sobecks, Gary J Schiller, Lisa Lupinacci, David Reiser, Judith Allen, Syed Rizvi

Blood (2009) 114 (22): 3886.

https://doi.org/10.1182/blood.V114.22.3886.3886

Published: 2009

Journal Articles

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

David Siegel, Sundar Jagannath, MD, Sagar Lonial, MD, Meletios A. Dimopoulos, Thorsten Graef, MD, PhD, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Syed Rizvi, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3890.

https://doi.org/10.1182/blood.V114.22.3890.3890

Published: 2009

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Kristy L. Richards, PhD, MD, Reynaldo Garcia, RN, OCN, John S. Strader, Madlyn Ferraro, RN, OCN, CCRC, Jennifer MacLean, RN, Diane Winans, Dominic T. Moore, PhD, Andrew Dodd, Matthew C. Foster, MD, Don A. Gabriel, MD, PhD, Thomas C. Shea, Jonathan Serody, MD, Hendrik W. van Deventer, MD, Syed Rizvi, Robert Z. Orlowski, M.D., Ph.D., David D. Hurd, MD

Blood (2009) 114 (22): 306.

https://doi.org/10.1182/blood.V114.22.306.306

Published: 2009

Journal Articles

Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study.

David Siegel, Donna M Weber, MD, Constantine S. Mitsiades, Meletios A. Dimopoulos, Jean-Luc Harousseau, Syed Rizvi, Jason Howe, David Reiser, Catriona Byrne, Kenneth C. Anderson, MD, Paul Richardson, MD, PhD

Blood (2009) 114 (22): 305.

https://doi.org/10.1182/blood.V114.22.305.305

Published: 2009

Journal Articles

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

Donna Weber, Ashraf Z. Badros, Sundar Jagannath, David Siegel, Victoria Richon, Syed Rizvi, Jose Garcia-Vargas, David Reiser, Kenneth C. Anderson

Blood (2008) 112 (11): 871.

https://doi.org/10.1182/blood.V112.11.871.871

Published: 2008

Journal Articles

A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

David Siegel, Donna Weber, MD, Constantine S. Mitsiades, MD, PhD, Syed Rizvi, Jose Garcia-Vargas, Jason Howe, David Reiser, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 3705.

https://doi.org/10.1182/blood.V112.11.3705.3705

Published: 2008

NARROW

Late Polyclonal P-BCMA-101 CAR-T Cell Re-Expansion and Rapid Complete Response in a Patient with Relapsed Multiple Myeloma Treated with One Cycle of Talquetamab, More Than 3 Years after CAR-T Infusion

A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort

A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety

Relationship Between Lenalidomide Dose Modification and Outcomes in Patients with Myelodysplastic Syndromes

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

The Combined Safety and Tolerability Profile of Vorinostat-Based Therapy for Solid or Hematologic Malignancies.

The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma.

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study.

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only